Skip to content
#protein folding Open access

Pre-Seasonal Treatment With Recombinant Carrier-Based Birch Vaccine Improves Birch Pollen Allergy.

Sep 2026 · Allergy. European Journal of Allergy and Clinical Immunology · 0 citations · 43 references
Medicine

Abstract

Background

We have recently reported the preclinical characterization of a recombinant birch pollen allergy vaccine based on a fusion protein, AB-PreS, consisting of allergen-derived peptides fused to the hepatitis B virus (HBV)-derived PreS surface protein as immunological carrier.

Objective

To investigate in a clinical study the usefulness of the AB-PreS vaccine, termed GNR-127, for allergen-specific immunotherapy of birch pollen allergy.

Methods

Stage 1 of the study, an open-label Phase I study, determined among three doses (20 μg: n = 6; 40 μg: n = 6; 80 μg: n = 6) administered as Aluminum-hydroxide-adsorbed vaccines subcutaneously five times in monthly intervals, the highest tolerated doses. In the following Stage 2, randomized patients (placebo: n = 45; 40 μg: n = 43; 80 μg: n = 44) received in a single-blind, placebo-controlled Phase II study monthly up to five pre-seasonal injections. Safety monitoring followed the Medical Dictionary for Regulatory Activities (MedDRA); efficacy parameters were determined according to the European Academy for Allergy and Clinical Immunology (EAACI) guidelines; allergen-specific antibodies and basophil sensitivity were determined by ELISA and basophil activation testing, respectively.

Results

A dose-dependent reduction of the combined symptom medication score (CSMS) (40 μg: 17.41%; 80 μg: 24.13%) over placebo was observed which was significant for the 80 μg group and accompanied by the strongest induction of Bet v 1-specific IgG (median 20-fold increase) and a blunting of the seasonally boosted IgE response and basophil sensitivity. The vaccine showed an acceptable safety profile despite high administered doses.

Conclusion

A pre-seasonal course of 5 monthly injections of GNR-127 80 μg improved symptoms of birch pollen allergy accompanied by a robust Bet v 1-specific IgG response, paving the road for a Phase III efficacy study. TRIAL REGISTRATION ClinicalTrials.gov (Identifier: NCT07155499).

Read PDF

Similar papers

#computer vision Review Open access May 2015

A survey study on major technical barriers affecting the decision to adopt cloud services

The comparison of adopter and non-adopter sample reveals three potential adoption inhibitor, security, data privacy, and portability, which underlines the importance of the technical and security perspectives for research investigating the adoption of technology.

Nattakarn Phaphoom, Xiaofeng Wang, S. Samuel et al. · 111 citations · ⚡8
#computer vision Open access Feb 2018

Lean Internal Startups for Software Product Innovation in Large Companies: Enablers and Inhibitors

This study investigates how Lean internal startup facilitates software product innovation in large companies and identifies its enablers and inhibitors, and shows the potential of the method-in-action framework to investigate the Lean startup approach in non-startup context.

Henry Edison, Nina M. Smørsgård, Xiaofeng Wang et al. · 78 citations · ⚡6
#computer vision Book Open access Jul 2015

Understanding the affect of developers: theoretical background and guidelines for psychoempirical software engineering

This paper highlights the challenges to conduct proper affect-related studies with psychology, provides a comprehensive literature review in affect theory, and proposes guidelines for conducting psychoempirical software engineering.

D. Graziotin, Xiaofeng Wang, P. Abrahamsson · 56 citations · ⚡4
#machine learning Open access May 2017

What Influences the Speed of Prototyping? An Empirical Investigation of Twenty Software Startups

This study conducts a multiple case study on twenty European software startups and proposes a prototype-centric learning model in early stage software startups, and identifies factors that occur as barriers but also facilitators for prototyping in earlystage software startups.

Anh Nguyen-Duc, Xiaofeng Wang, P. Abrahamsson · 44 citations · ⚡5
#protein folding Open access Sep 2026

Programmable design of functional proteins from natural language

Pinal, a 16-billion-parameter foundation model that produces protein candidates from natural-language functional descriptions, supports natural language as a high-level interface for candidate generation in protein design, enabling programmable exploration with reduced reliance on manually specified structural or sequence constraints.

Fengyuan Dai, Shiyang You, Yudian Zhu et al. · 31 citations · ⚡3

Related blog posts

MIT News · Artificial Intelligence Aug 27, 2026

Looking beyond natural sequences

A new machine-learning framework aims to improve the success rate of computational protein design while moving away from results that reproduce sequences found in nature.

Google DeepMind Blog Nov 25, 2025

AlphaFold: Five years of impact

Explore how AlphaFold has accelerated science and fueled a global wave of biological discovery.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.